论文部分内容阅读
目的观察孟鲁司特联合舒利迭治疗咳嗽变异性哮喘的临床疗效。方法将我院2007年12月-2009年12月收治的110例咳嗽变异性哮喘患者随机分为治疗组55例和对照组55例,治疗组给予孟鲁司特联合舒利迭治疗,对照组则单独吸入舒利迭治疗,两组疗程均为8周,一个疗程后评价疗效,并随访观察复发情况。结果治疗组的总有效率明显高于对照组,两组相比较有显著性差异(P<0.05);其症状缓解及消失时间均短于对照组(P﹤0.05);复发率及不良反应也低于对照组(P<0.05)。结论孟鲁司特联合舒利迭治疗咳嗽变异性哮喘疗效显著,使用安全,且复发率低,值得临床上推广。
Objective To observe the clinical efficacy of montelukast combined with seretide in the treatment of cough variant asthma. Methods One hundred and ten patients with cough variant asthma admitted from December 2007 to December 2009 in our hospital were randomly divided into treatment group (55 cases) and control group (55 cases). The treatment group was treated with montelukast and seretide and the control group Then inhaled seretide alone treatment, two courses of treatment were 8 weeks after a course of evaluation of efficacy and follow-up observation of recurrence. Results The total effective rate in the treatment group was significantly higher than that in the control group (P <0.05). The symptoms and the disappearance time of the treatment group were shorter than those in the control group (P <0.05). The recurrence rate and adverse reactions Lower than the control group (P <0.05). Conclusion Montelukast combined with seretide for the treatment of cough variant asthma significant effect, safe to use, and the recurrence rate is low, it is clinically worthy of promotion.